Allulose does raise GLP-1 in humans, but only at doses far larger than a spoon of sweetener. In a 2022 trial in The Journal of Nutrition, 25 g delivered straight into the stomach raised GLP-1, PYY and CCK. At the 5 to 10 g people actually eat, the well-evidenced effect is on post-meal blood glucose.
Does allulose raise GLP-1?
Allulose raises GLP-1 in humans, and the evidence for it is real but narrow. One controlled human trial has measured it directly. Rodent work in Nature Communications found a bigger one. None of them show a GLP-1 response from the quantity in a normal serving of sweetener.
GLP-1 is a hormone your gut releases after you eat. It tells the pancreas to release insulin, slows how fast your stomach empties, and signals fullness to the brain. Semaglutide and tirzepatide work by mimicking it.
So anything that nudges your own GLP-1 upward is worth a look. The question is how far the nudge goes, and whether it survives contact with a real serving size.
Both things can be true at once. Allulose is a genuinely useful sweetener, and the Ozempic comparison it collects on Instagram doesn't survive a look at the doses.
The short version, ranked by how well each one is evidenced: post-meal glucose first, GLP-1 second, body weight a distant third.
What did the human research actually measure?
One human trial has measured allulose and GLP-1 directly. Teysseire and colleagues, in The Journal of Nutrition in 2022, gave 18 healthy young adults 25 g of D-allulose through a tube into the stomach. GLP-1, PYY and CCK all rose significantly compared with water.
That dose matters. 25 g is about five level teaspoons of the pure powder, taken in one hit and delivered straight past the mouth.
The same trial ran 50 g of erythritol alongside it. Erythritol raised fullness and slowed gastric emptying. Allulose did neither, despite lifting the same three hormones.
That's the finding, and it doesn't flatter the sweetener we make. We're printing it anyway, because a page that reports only the convenient half of a study isn't worth citing.
The dramatic results live in the rodent work. Iwasaki and colleagues, in Nature Communications in 2018, gave mice and rats 0.3 to 3 g per kg of body weight and recorded GLP-1 release, vagus nerve activation, less food eaten and less visceral fat.
Scaled to a 70 kg human, the bottom of that range is 21 g and the top is 210 g. Rodent metabolism doesn't map onto ours one for one, and the authors never claimed it did.
How much would you need for a GLP-1 effect?
The GLP-1 response in humans has only been shown at 25 g of allulose. A single-serve sweetener sachet is 5 g, and how much of that is allulose depends on the blend. So a spoon in your chai isn't delivering a study dose, and no honest label can promise it does.
| Allulose in one sitting | What the evidence supports | Source |
|---|---|---|
| 5 g | Lower post-meal blood glucose | Tani et al., PLOS One, 2023 |
| 10 g | Lower post-meal blood glucose | Tani et al., PLOS One, 2023 |
| 25 g | Higher GLP-1, PYY and CCK | Teysseire et al., J Nutr, 2022 |
| 28 g (70 kg adult) | Tolerance ceiling for a single dose | Han et al., Nutrients, 2018 |
That makes the pack worth reading properly. Most sweeteners list their ingredients without breaking out how much of each one you're getting, and the nutrition panel is usually where the real answer sits.
Line up the last two rows and you get the real constraint. The dose that moved GLP-1 in humans sits within a few grams of the largest single dose the tolerance research recommends, which is 0.4 g per kg of body weight.
For a 70 kg adult that ceiling is about 28 g. The study dose was 25 g. There isn't much daylight between a GLP-1 response and an afternoon you'd rather not discuss.
Is allulose a natural alternative to Ozempic or Mounjaro?
Allulose is not an alternative to Ozempic, Wegovy or Mounjaro, and anyone selling it that way is overreaching. Semaglutide and tirzepatide are GLP-1 receptor drugs, dosed weekly and titrated by a doctor. It's a sweetener that produces a small, brief hormone response at a dose most people won't eat.
The India context makes this less abstract than it was two years ago. Mounjaro launched here in March 2025 and became the country's top-selling drug by value inside seven months, doing roughly ₹100 crore in October 2025 alone across about 85,000 units.
India's GLP-1 drug market was worth around ₹606 crore as of July 2025, up about 27% on the year, according to market data reported by India Briefing. That's a lot of people with a new and specific interest in what goes into their coffee.
Sweetener brands have noticed. "Nature's Ozempic" is an easy claim to make and a hard one to check, which is the sort of claim that eventually gets checked by someone with a regulatory mandate.
Can you use allulose while you're on a GLP-1 medication?
Allulose is a reasonable sweetener to use while you're on semaglutide or tirzepatide, and we're not aware of any reported interaction. The catch is your gut. Both the medication and a large dose of it can upset digestion, so the effects stack. Ask your doctor, and start with a small amount.
People on these drugs eat less and eat differently. Appetite drops, sweet cravings often drop with it, and whatever's left has to earn its place in a much smaller daily intake.
A zero-calorie sweetener fits that pattern well. A teaspoon of sugar in chai is 16 calories and a glucose load your medication is already working against.
Nausea is the most common side effect of these drugs in the first months, and a big serving of any rare sugar or sugar alcohol can add to it. Build up over a week or two rather than switching everything in a day.
None of this is medical advice and your prescriber knows your case. Raise it at your next appointment rather than reading it off a blog.
What does allulose do reliably at everyday doses?
Allulose lowers post-meal blood glucose at 5 to 10 g, which is a realistic serving. Tani and colleagues pooled eight human experiments in PLOS One in 2023 and found both doses cut the glucose rise after a meal. The effect is consistent, and it's smaller than a diabetes drug's.
A 2026 systematic review in the American Journal of Clinical Nutrition pooled 20 controlled human trials of allulose and tagatose across more than 1,000 people. The acute glucose and insulin blunting held up with high certainty.
That same review found no meaningful effect on body weight, BMI, body composition or blood lipids in trials running from four weeks to a year. If you're eating allulose to lose weight, that's the number to sit with.
The rest is true and unexciting. Allulose carries about 0.4 calories per gram, roughly 70% of it is absorbed and passed out unchanged in urine within a day, and the remainder goes to the large intestine. The FDA grants it GRAS status and leaves it out of added sugars on the label, which we covered in why the FDA doesn't count allulose as a sugar.
Sugar claims on the front of a pack have their own rules, and they are not obvious. We've laid out the three sugar claims and what each one guarantees.
Monk fruit does a different job in the same spoon. Mogrosides are hundreds of times sweeter than sugar and carry the sweetness, while allulose carries the bulk, the browning and the mouthfeel. That's the reason our blend uses monk fruit, the other half of the pack, alongside it.
How much allulose is too much?
Han and colleagues, publishing in Nutrients in 2018, set the maximum tolerated single dose of allulose at 0.4 g per kg of body weight, and the daily maximum at 0.9 g per kg. For a 70 kg adult that works out at about 28 g in one sitting and 63 g across a day.
The 2021 review in the British Journal of Nutrition reads it more conservatively and applies 0.4 g per kg to the daily total as well. Either way the ceiling is real, and it's lower than most people assume.
Some of our own customers report bloating. It's a small number, it's usually dose-related, and it's why we tell people to start with half of what they think they need.
Building up over a week or two usually settles it. That's true of most fermentable sugars and it's true here. If you're managing blood sugar day to day, our guide to sugar substitutes for diabetics in India covers the practical side.
What we still don't know about allulose and GLP-1
Nobody has yet run a human trial of allulose at a realistic serving size, eaten normally, with GLP-1 as the primary outcome. The one human GLP-1 study used a stomach tube and a dose five times a normal serving. Everything below that dose is extrapolation.
Daniel and colleagues put it plainly in the British Journal of Nutrition in 2021. Whether allulose's metabolic activity is relevant in humans is not known, and there's a clear shortage of human studies at realistic doses.
That's shifting slowly. A randomised crossover trial comparing allulose against aspartame on post-meal GLP-1 published its protocol in JMIR Research Protocols in 2026, which tells you where the field is. Still designing the study that would settle it.
Three questions stay open: whether repeated daily doses do anything single-dose studies miss, whether the response differs in people with type 2 diabetes, and whether an Indian meal pattern changes any of it. We'll update this page when there's an answer worth reporting.
Where these numbers come from
Every figure on this page comes from published human or animal research, named in the text with its journal and year. Beyond The Sugar has lab reports, certifications and supplier COAs for its own products. It has no clinical research of its own, and nothing here should be read as ours.
- Teysseire F, et al. (2022). The role of D-allulose and erythritol on the activity of the gut sweet taste receptor and gastrointestinal satiation hormone release in humans: a randomized, controlled trial. The Journal of Nutrition. PubMed 35135006
- Tani Y, et al. (2023). Allulose for the attenuation of postprandial blood glucose levels in healthy humans: a systematic review and meta-analysis. PLOS One. Read the meta-analysis
- Glycemic and cardiometabolic effects of rare sugars allulose and tagatose: a systematic review and meta-analysis of controlled human intervention trials (2026). American Journal of Clinical Nutrition. Read the 2026 review
- Iwasaki Y, et al. (2018). GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nature Communications. Read the rodent study
- Han Y, et al. (2018). Gastrointestinal tolerance of D-allulose in healthy and young adults: a non-randomized controlled trial. Nutrients. PubMed 30572580
- Daniel H, et al. (2021). Allulose in human diet: the knowns and the unknowns. British Journal of Nutrition. Read the review
Frequently asked questions
Will allulose help me lose weight?
Allulose won't do that work on its own. A 2026 review in the American Journal of Clinical Nutrition pooled 20 human trials and found no meaningful change in body weight, BMI or body composition. Swapping sugar for it removes calories from your day, and that's the honest mechanism.
Does allulose raise insulin?
Allulose doesn't raise insulin meaningfully. Human trials record a flat or reduced insulin response compared with sugar, and the 2026 review in the American Journal of Clinical Nutrition found it blunted post-meal insulin. Your body doesn't metabolise it for energy, so there's little for insulin to act on.
How much allulose can I have in a day?
Han and colleagues, in Nutrients in 2018, put the tolerated maximum at 0.4 g per kg of body weight in one dose and 0.9 g per kg across a day. For a 70 kg adult that's roughly 28 g at once and 63 g daily. Most people use far less.
Does allulose break a fast?
Allulose carries about 0.4 calories per gram and doesn't move blood glucose or insulin meaningfully, so on a metabolic definition of fasting it doesn't break one. On a strict zero-calorie definition it does. Pick whichever definition you're actually fasting for and go with that.
Is allulose safe for people with type 2 diabetes?
Allulose has been tested in people with type 2 diabetes, including a 2023 pilot crossover study in Nutrients by Fukunaga and colleagues. It doesn't raise blood glucose and it lowers the glucose rise from a meal. Your medication and targets are your doctor's call, so check before changing anything.
Does allulose cause bloating or gas?
Allulose causes bloating in some people, usually above roughly 0.4 g per kg of body weight in a single sitting. Starting with half a normal serving and building up over a week or two usually settles it. That said, its gut tolerance is much better than sugar alcohols like erythritol and maltitol, that are common in current food and beverage products in the market.
If you landed here from a post calling allulose a natural Ozempic, now you know where that claim runs out. It's a very good sweetener with one well-evidenced metabolic effect and a queue of research still to come.
Our blend is FSSAI approved and has no erythritol, no cooling effect and no chemical finish. It goes into chai, coffee, kheer and baking without the flat sweetness monk fruit gives you on its own.
The same two ingredients do the work in our zero added sugar choco hazelnut spread, which carries 3.3 g of total sugar per 100 g, all of it lactose from milk solids, and uses coconut and groundnut oil instead of palm.
Try our monk fruit and allulose blend, or read our full guide to what allulose is and how it works for the rest of the evidence.
This article is for information, not medical advice. If you're managing diabetes or taking a GLP-1 medication, talk to your doctor before changing what you eat.